Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q1 FY26 results · Apr–Jun 2025
Natco Pharma reported revenue from operations of ₹1,328.90 crore (down 2.5% from Q1 FY25) and net profit of ₹480.30 crore (down 28.2% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,328.90 | 1,362.60 | −2.5% | 1,221.00 | +8.8% |
| Other income | 61.70 | 48.10 | +28.3% | 66.30 | −6.9% |
| Total income | 1,390.60 | 1,410.70 | −1.4% | 1,287.30 | +8.0% |
| Profit before tax | 571.90 | 803.60 | −28.8% | 505.90 | +13.0% |
| Net profit for the period | 480.30 | 668.50 | −28.2% | 406.00 | +18.3% |
| Attributable to shareholders of the company | 480.70 | 668.50 | −28.1% | 406.60 | +18.2% |
| EPS, basic (₹) | 26.84 | 37.32 | −28.1% | 22.70 | +18.2% |
| Net margin (%) | 36.1 | 49.1 | 33.3 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,192.70 | 1,236.90 | −3.6% | 1,157.40 | +3.0% |
| Other income | 59.60 | 39.80 | +49.7% | 62.10 | −4.0% |
| Total income | 1,252.30 | 1,276.70 | −1.9% | 1,219.50 | +2.7% |
| Profit before tax | 542.90 | 758.00 | −28.4% | 520.80 | +4.2% |
| Net profit for the period | 464.10 | 636.30 | −27.1% | 428.10 | +8.4% |
| EPS, basic (₹) | 25.91 | 35.53 | −27.1% | 23.90 | +8.4% |
| Net margin (%) | 38.9 | 51.4 | 37.0 |
Consolidated
- Filed with BSE
- 12 Aug 2025, 15:18 IST
- Board meeting
- 12 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Aug 2025, 15:18 IST
- Board meeting
- 12 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE